Back to Search
Start Over
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
- Source :
- PLoS ONE, Vol 16, Iss 12, p e0261994 (2021)
- Publication Year :
- 2021
- Publisher :
- Public Library of Science (PLoS), 2021.
-
Abstract
- [This corrects the article DOI: 10.1371/journal.pone.0054014.].
Details
- Language :
- English
- ISSN :
- 19326203
- Volume :
- 16
- Issue :
- 12
- Database :
- Directory of Open Access Journals
- Journal :
- PLoS ONE
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.3a8c73388258421cbed41f983d337c90
- Document Type :
- article
- Full Text :
- https://doi.org/10.1371/journal.pone.0261994